<DOC>
	<DOCNO>NCT01173068</DOCNO>
	<brief_summary>The aim study determine outcome use ertapenem complicate urinary tract infection OPAt setting . The study hypothesis : Ertapenem efficacious safe therapeutic option complicate urinary tract infection OPAt setting .</brief_summary>
	<brief_title>An Observational Study Ertapenem Outpatient Parenteral Antibiotic Therapy ( OPAT ) Complicated Urinary Tract Infections .</brief_title>
	<detailed_description>Enterobactericae spp . common cause urinary tract infection . The prevalence quinolone-resistance Enterobactericae rise often co-exists expression extended-spectrum beta-lactamase ( ESBL , limit viable outpatient therapeutic option . In Singapore , increase trend treat patient respond favourably initial antimicrobial therapy outpatient setting ( Fisher , et.al , 2006 ) . Ertapenem one several agent excellent antimicrobial activity Enterobactericae ( include ESBL producer ) . In view safety profile viability elastromeric pump , great potential use OPAT patient . There study analyze outcome large cohort patient complicate urinary tract infection treat ertapenem .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Ertapenem</mesh_term>
	<criteria>Adult patient 21 year old 70 year old . Diagnosed complicate urinary tract infection due pathogen susceptible ertapenem base microbiology report , use ertapenem deem clinically appropriate Infectious Disease physician charge . Hypersensitivity reaction Ertapenem . Participation another interventional clinical investigation within 30days Unable obtain informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Ertapenem</keyword>
	<keyword>Clinical outcome</keyword>
	<keyword>Complicated Urinary Tract Infections</keyword>
</DOC>